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Abstract Electroporation-based treatments and other
therapies that permeabilize the plasma membrane have
been shown to be more devastating to malignant cells than
to normal cells. In this study, we asked if a difference in
repair capacity could explain this observed difference in
sensitivity. Membrane repair was investigated by disrupt-
ing the plasma membrane using laser followed by moni-
toring fluorescent dye entry over time in seven cancer cell
lines, an immortalized cell line, and a normal primary cell
line. The kinetics of repair in living cells can be directly
recorded using this technique, providing a sensitive index
of repair capacity. The normal primary cell line of all tested
cell lines exhibited the slowest rate of dye entry after laser
disruption and lowest level of dye uptake. Significantly,
more rapid dye uptake and a higher total level of dye
uptake occurred in six of the seven tested cancer cell lines
(p\ 0.05) as well as the immortalized cell line
(p\ 0.001). This difference in sensitivity was also
observed when a viability assay was performed one day
after plasma membrane permeabilization by electropora-
tion. Viability in the primary normal cell line (98 % viable
cells) was higher than in the three tested cancer cell lines
(81–88 % viable cells). These data suggest more effective
membrane repair in normal, primary cells and supplement
previous explanations why electroporation-based therapies
and other therapies permeabilizing the plasma membrane
are more effective on malignant cells compared to normal
cells in cancer treatment.
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Introduction
Electroporation is increasingly being used in cancer treat-
ment strategies (Kee et al. 2011). It is a method where
application of short, high-voltage pulses induces transient
permeabilization of the cell membrane and thus allows the
passage of ions and molecules into and out of the cell
(Orlowski and Mir 1993; Gehl 2003; Frandsen et al. 2012;
Vasquez et al. 2015). The membrane reseals within a few
minutes depending on the parameters used (reversible
electroporation) and if the electric field is high enough, the
membrane does not reseal and results in irreversible elec-
troporation (Rols and Teissie 1990). Clinically, in anti-
cancer treatments, this method is used as irreversible
electroporation (without added drugs) (Martin et al. 2015)
and as reversible electroporation in combination with
chemotherapeutic drugs (electrochemotherapy) (Belehra-
dek et al. 1993; Marty et al. 2006; Matthiessen et al. 2012),
calcium (calcium electroporation) (ClinicalTrials.gov ID-
NCT01941901), and DNA drugs (gene electrotransfer)
(Mir et al. 1999; Daud et al. 2008; Spanggaard et al. 2013).
Electrochemotherapy is standardly used for the treatment
of cutaneous metastases, and clinical trials for the treat-
ment of internal tumors are ongoing using new electrode
designs (Edhemovic et al. 2011). Interestingly, it has been
a consistent clinical observation that normal tissue is much
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less affected than malignant tissues when treating with
electrochemotherapy (Fig. 1; Gehl 2005) as well as with
irreversible electroporation (Neal et al. 2011). Recently,
similar results for calcium electroporation were shown in a
3D in vitro model where normal cell spheroids were much
less affected by calcium electroporation than cancer cell
spheroids (Frandsen et al. 2015). It has also been shown
in vitro that sonoporation, a method where application of
low-power ultrasound permeabilizes the cell membrane,
causes different effects in normal and malignant cells
(Lejbkowicz et al. 1993; Lejbkowicz and Salzberg 1997).
These differences in sensitivity between normal and
cancer cells when permeabilizing the plasma membrane,
independent of the method used, could indicate a differ-
ence in susceptibility of cells to permeabilization treat-
ments or the capacity to rapidly reseal after
permeabilization. We aimed to investigate if differences in
membrane repair in a number of cancer cell lines, an
immortalized cell line, and a normal primary cell line could
be part of the explanation for the observed difference in
sensitivity between normal and cancer cells for treatments
using permeabilization methods. The extent of permeabi-
lization after electroporation is known to depend on dif-
ferent factors including membrane composition (Levine
and Vernier 2012), cell size (Teissie and Rols 1993), cell
shape (Pucihar et al. 2006), and cell density (Pucihar et al.
2007) in the suspension. To our knowledge the observed
difference in sensitivity between malignant and normal
cells has been an empirical finding, for which mechanisms
still need to be elucidated. We therefore decided to
investigate membrane repair by disrupting the plasma
membrane using laser technology, since holes created by
laser, in contrast to permeabilization after electroporation,
are equal in size independent of cell type (Bansal et al.
2003; Howard et al. 2011a, b), allowing us to investigate
membrane repair separately from the level of membrane
poration. We show that when using a laser to disrupt the
plasma membrane in the presence of a fluorescent dye, the
rate and extent of dye entry in the normal dermal fibroblast
was the lowest in all tested cell lines and significantly
reduced compared to that in six of the seven tumor-derived
cell lines as well as the immortalized cell line. Thus, the
normal fibroblast cell line appeared to have a faster
membrane repair. These empiric observations could help
explain the differential sensitivity to electrochemotherapy
and calcium electroporation between normal and malignant
cells.
Materials and Methods
This was a collaborative study where the laser experiments
were performed in Georgia, USA and the electroporation
experiments were performed in Copenhagen, Denmark.
Cell Culture
Nine different human cell lines were used in this study;
seven cancer cell lines, an immortalized normal cell line,
and one primary normal cell line (Table 1). (1) H69, a
small cell lung carcinoma kindly provided by the Depart-
ment of Radiation Biology, Copenhagen University
Hospital, Denmark (Gjetting et al. 2010), (2) HT29, a
colorectal adenocarcinoma (ATCC #HTB-38), (3) MKN-
28, a gastric adenocarcinoma and (4) MKN-45, a gastric
carcinoma kindly provided by Dr. Katsuya Miyake,
Kagawa University, Japan (Fukui et al. 2003), and (5) PC3-
M, a prostate cancer derived from a bone metastasis
(ATCC #CRL-1435). These cell lines were all grown in
RPMI-1640 culture medium (Gibco, Invitrogen). (6)
MRC5, an immortalized lung fibroblast (ATCC #CCL-
171) was grown in EMEM culture medium (Gibco, Invit-
rogen). (7) MDA-MB-231, a breast adenocarcinoma
(ATCC #HTB-26), (8) SW780, a bladder transitional cell
Fig. 1 Malignant melanoma treated with electrochemotherapy. Pic-
tures of a malignant melanoma patient before (left), 1 month (middle),
and 6 months (right) after treatment with electrochemotherapy using
bleomycin showing complete remission of the tumor 6 months after
treatment. Note the needle marks seen in surrounding normal tissue
1 month after treatment showing that normal tissue is much less
affected by electrochemotherapy then the cancer tissue (Gehl 2005)
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carcinoma kindly provided by Dr. Lars Dyrskjøt Andersen,
Department of Molecular Medicine, Aarhus University
Hospital, Skejby, Denmark (Herbsleb et al. 2008), and (9)
primary normal human dermal fibroblasts HDF-n kindly
provided by Dr. Marie-Pierre Rols, Institute of Pharma-
cology and Structural Biology, IPBS, Toulouse, France
(Frandsen et al. 2015) were grown in DMEM culture
medium (Gibco, Invitrogen). All cells grew with 10 % fetal
calf serum (Gibco, Invitrogen), 100 U/ml penicillin, and
100 lg/ml streptomycin and were maintained at 37 C and
5 % CO2. All cells were tested negative for mycoplasma
using MycoAlert mycoplasma detection kit (Lonza).
Membrane Repair
A well-characterized assay (Bansal et al. 2003) was used to
assess membrane repair. Membrane repair is initiated by
creating a lesion of a well-defined size and shape (software
selectable) in cells immersed in the dye, FM1-43. Previous
studies have demonstrated that lesions of a defined size can
reproducibly be made using this technique (Bansal et al.
2003; Howard et al. 2011a, b). FM1-43 is non-fluorescent
in water, but highly fluorescent in a non-polar environment,
such as cell membranes. It is capable moreover of rapidly
partitioning into and out of lipid bilayers, but cannot cross
them. In the absence of a lesion, therefore, only the surface
lipid bilayer, the plasma membrane, is labeled, as well as
over time (hours) endosomal pathway membranes. Over
the time course of the typical repair experiment, this
endocytotic accumulation of fluorescence is however
insignificant (Bansal et al. 2003; Howard et al. 2011a; b).
When a membrane lesion is created with the laser, dye in
medium can freely enter the cell, where it then partitions
into internal membrane compartments, adding internal
fluorescence signal. Accumulation of this signal continues
until repair is completed. Continuing accumulation of
internal fluorescence, recorded by measuring integrated
cellular fluorescence signal over time, therefore provides
an accurate record of the duration of lesion opening, and
the cessation of dye accumulation marks repair completion.
Briefly, cultured cells were wounded in PBS, with or
without 1.2 mM Ca2?, containing 2.5 lM FM 1-43 (In-
vitrogen). Laser injury was produced using a 2-photon laser
scanning confocal microscope (LSM 780 Multiphoton
Microscope, Zeiss) coupled to a Vision S tunable laser
(Coherent) at 100 % power (one laser iteration and a 15
pixels diameter circle bleach area placed over the mem-
brane edge), creating 1.66 lm diameter plasma membrane
disruptions. Fluorescence intensity over time was quanti-
fied using ZEN 2012, Zeiss software.
Table 1 Cell lines used in this study
Cell line Phenotype characteristics Source References
H69 Human small cell lung carcinoma Kindly provided by the Department of Radiation
Biology, Copenhagen University Hospital, Denmark
Gjetting et al. (2010)
HDF-n Human primary normal human dermal
fibroblasts (not immortalized)
Kindly provided by Dr. Marie-Pierre Rols, Institute of
Pharmacology and Structural Biology, IPBS,
Toulouse, France
Frandsen et al. (2015)
HT29 Human colorectal adenocarcinoma ATCC #HTB-38 http://atcc.org/
Products/All/HTB-
38.aspx
MDA-MB-231 Human breast adenocarcinoma ATCC #HTB-26 http://atcc.org/
Products/All/HTB-
26.aspx
MKN-28 Human gastric adenocarcinoma Kindly provided by Dr. Katsuya Miyake, Kagawa
University, Japan
Fukui et al. (2003)
MKN-45 Human gastric carcinoma Kindly provided by Dr. Katsuya Miyake, Kagawa
University, Japan
Fukui et al. (2003)
MRC5 Immortalized human lung fibroblast ATCC #CCL-171 http://atcc.org/
Products/All/CCL-
171.aspx
PC3-M Human prostate cancer derived from a
bone metastasis
ATCC #CRL-1435 http://atcc.org/
Products/All/CRL-
1435.aspx
SW780 Human bladder transitional cell
carcinoma
Kindly provided by Dr. Lars Dyrskjøt Andersen,
Department of Molecular Medicine, Aarhus University
Hospital, Skejby, Denmark
Herbsleb et al. (2008)
The name, phenotype characteristics, source, and references of the nine different cell lines used in this study are presented in the table
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Viability After Electroporation (With or Without
Added Calcium)
The primary normal cell line (HDF-n) and three cancer cell
lines (HT29, MDA-MB231, and SW780) were tested for
viability after electroporation. These cell lines were chosen
to compare the normal cell line with a few of the cancer
cells lines that had shown a clear difference in membrane
repair.
After harvesting, cells were washed in HEPES buffer
(10 mM HEPES, 250 mM sucrose, and 1 mM MgCl2 in
sterile water) and diluted to 5.5 9 106 cells/ml HEPES
buffer. In 4 mm cuvettes with aluminum electrodes
(Molecular BioProducts, Inc.) 300 ll cooled cells (8 C)
were electroporated by delivering 8 pulses of 100 ls,
1.2 kV/cm, and 1 Hz using a BTX T820 square wave
electroporator. After 20 min incubation at 37 C and 5 %
CO2 cells were diluted in culture medium to 3.1 9 10
5
cells/ml and seeded in 96-well plates (100 ll/well). One
day after treatment viability was measured by MTS assay
(Malich et al. 1997) using Multiskan-Ascent ELISA reader
(Thermo Labsystems).
Permeabilization After Electroporation
The primary normal cell line (HDF-n) and the bladder
cancer cell line (SW780) were tested for degree of per-
meabilization after electroporation. These cell lines were
chosen since they showed a significant difference in via-
bility after electroporation.
Cells were plated in Willco wells (30.000 cells in 2 ml
medium; WillCo Wells BV, The Netherlands) one day
prior to experiments. Cells were washed in 1 ml Krebs–
Ringer buffer (25 mM Na-gluconate, 120 mM NaCl,
1 mM MgCl26H2O, 0.4 mM KH2PO4, 1.6 mM K2HPO4
3H2O, 1.5 mM CaCl22H2O, 10 mM glucoseH2O in MiliQ
water) before adding 400 ll Krebs–Ringer buffer con-
taining 1 lM YO-PRO-1 (Invitrogen) and incubated at
37 C and 0 % CO2 for 30 min. YO-PRO-1 is a fluorescent
dye that binds to nucleic acids after entering cells when
plasma cell membranes are permeabilized (e.g., electro-
poration, during apoptosis, induction of pore channels).
Cells were treated with electroporation (8 pulses of 1.2 kV/
cm, 100 ls, and 1 Hz) using a Cliniporator (IGEA, Italy)
and a custom-made contact copper electrode with 8 mm
between the electrodes (Fig. 2). Electroporation parameters
were optimized for both cell lines for high permeabilization
and high viability, and the same parameters were used for
both cell lines. Pictures were taken before treatment and
3 min after treatment using a Leica DMI6000B microscope
connected to a Leica DFC450C camera. Mean fluorescence
intensity in cells was calculated using Image J software
(NIH, Bethesda, USA).
Graphics and Statistics
All artwork was created using GraphPad Prism 6. Statis-
tical analyses were performed using SAS software (version
9.2). Difference in fluorescence intensity in the different
cell lines was evaluated as repeated measurements, vali-
dated and analyzed with an exponential decrease model
with Bonferroni correction. ‘‘Cell line,’’ ‘‘Time,’’ and ‘‘n’’
were used as factors and baseline level of fluorescence
intensity were used as covariant. Difference in viability
after electroporation between different cell lines and dif-
ference in permeabilization after electroporation between
HDF-n and SW780 cell lines were assessed using one-way
analysis of variance (ANOVA) with Bonferroni correction.
Difference in viability after electroporation with addition
of calcium between HDF-n and HT29 cell lines was
assessed using two-way ANOVA with Bonferroni
correction.
Results and Discussion
To compare membrane repair in different cancer cell lines,
an immortalized cell line, and a normal primary cell line,
we measured the rate and extent of fluorescent dye entry
after rupture of the plasma membrane using a laser
(Figs. 3, 4). Nine different cell lines (seven cancer cell
lines, an immortalized cell line, and a normal primary cell
line) were tested to investigate membrane repair in a
variety of different tumor types. The method used for
testing membrane repair is a well-known method where a
disruption in the plasma membrane is created using a laser
(Bansal et al. 2003). This creates 1.66 lm diameter plasma
membrane disruptions, and the size of the disruption does
not depend on the cell type. The fluorescent dye enters
Fig. 2 Custom-made contact copper electrode. Picture of the elec-
trode used for the experiment testing permeabilization after electro-
poration. The electrode is made to fit in a Willco Well
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through the membrane disruption, but further entry is
hindered when plasma membrane repair is initiated. Prior
dye entry by endocytosis into cytoplasm is ignored (sub-
traction of signal during analysis) and entry during the
repair measurement is insignificant (second time scale).
The rate and extent of dye entry in the normal primary cells
was the lowest of all tested cell lines and significantly
reduced compared to all the tumor-derived lines (p\ 0.05)
with one exception being the PC3-M cell line derived from
a bone metastasis of a prostate cancer (p = 0.29) (Fig. 3).
In five of seven cancer-derived cell lines, dye entry con-
tinued throughout the time course of the experiment
(360 s). Thus, membrane repair either failed or was less
effective in these tumor-derived cell lines indicating a less
efficient membrane repair system. Especially HeLa cells
have a much less effective membrane repair than all the
other tested cell lines (Figs. 3a, 4). The immortalized
normal cell line (MRC5, a human lung cell line) showed a
slightly higher dye entry than the primary normal cell line
(Fig. 3a). However, dye entry in the immortalized cell line
was still in the lower half of the tested cell lines. Possible
changes in membrane composition and/or membrane
function when immortalizing the cell line may explain why
this cell line does not exhibit dye entry equivalent to the
primary normal cells. However, further investigations are
needed to clarify if normal and immortalized cell lines in
general show difference in membrane repair.
As previously described, permeabilization induced by
electroporation depends on the cell type (membrane com-
position, cell size, and cell shape) (Teissie and Rols 1993;
Pucihar et al. 2006; Levine and Vernier 2012). Differences
in viability after electroporation have previously been
explained by differences in permeabilization due to the
different cell types. However, this study suggests that dif-
ferences in membrane repair after permeabilization might
also affect the viability. Electroporation induces perme-
abilization of the plasma membrane with more but smaller
pores (Gehl 2003; Levine and Vernier 2012) compared
with laser disruption, and this might lead to different repair
mechanisms in the two cases.
To test if this difference in membrane repair has an
effect on viability when permeabilizing the plasma mem-
brane by electroporation, we electroporated four of the
used cell lines (three cancer cell lines and the normal pri-
mary cell line, previously used in another study (Frandsen
et al. 2015)) and measured viability one day after treatment
(Fig. 5). The normal primary cells showed the highest
viability (98 %) after electroporation, significantly higher
Fig. 3 Membrane repair capability. Intensity of FM1-43 in nine
different cell lines (seven cancer cell lines, an immortalized cell line,
and a normal primary cell line) after disrupting the plasma membrane
using laser. a All tested cell lines including the immortalized cell line
and the HeLa cell line. b Six of the tested cancer cell lines and the
normal primary cell line, (note the changed y-axis). Data are shown as
mean ? SEM, n = 7–22, significance at 360 s shown, *p\ 0.05,
**p\ 0.01, ***p\ 0.001, ****p\ 0.0001, ns not significant
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than viability of the SW780 cancer cell line (81 %,
p\ 0.05). This difference in viability after electroporation
in the normal primary cell lines and the SW780 cancer cell
line was not caused by lower permeabilization after elec-
troporation of the normal cells. Actually, when testing
permeabilization after electroporation in the two cell lines
in the presence of the fluorescent dye YO-PRO-1, we
showed that uptake of the dye was significantly higher in
the normal cell line than in the cancer cell line. This
indicates higher degree of permeabilization of the normal
cell line after electroporation, when using the same
Fig. 4 Images of FM1-43
intensity. Representative images
of three cancer cells (HeLa,
HT29, SW780) and a normal
primary cell (HDF-n) showing
fluorescence before and 40, 120,
and 200 s after disrupting the
plasma membrane using a laser
in the presence of FM1-43.
Scale bar in bottom right corner
is 10 lm
Fig. 5 Viability after electroporation. Viability measured using MTS
assay one day after electroporation (8 pulses of 1.2 kV/cm, 100 ls,
and 1 Hz) of three cancer cell lines (HT29, MDA-MB231, and
SW780) and a normal primary cell line (HDF-n). Data are shown as
mean ? SD n = 3–6, *p\ 0.05
Fig. 6 Permeabilization after electroporation. A normal primary cell
line (HDF-n) and a bladder cancer cell line (SW780) electroporated in
the presence of the non-permeant dye Yo-Pro-1. Fluorescence
intensity was measured 3 min after electroporation. Data are shown
as mean ? SD n = 4, *p\ 0.05
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electroporation parameters for both cell lines (Fig. 6). In
other words, the normal cell line does get permeabilized by
electroporation (even to a higher extent than the malignant
cell line tested), but repairs faster when a direct comparison
is made as the laser holes are comparable across cell lines.
Thus, normal cells seem to recover more effectively, likely
explaining the higher survival rate (Fig. 5). Survival after
electroporation is determined by a number of factors,
including the degree of membrane permeabilization, but
also energy level and other intracellular factors. As seen in
Fig. 3, there is a significant difference in membrane repair
between normal and malignant cell lines, which may in
part explain the difference in survival after electroporation.
However, a more pronounced difference of late membrane
repair would ensue when drugs (such as bleomycin) were
added.
The results of this study indicate that there is a reduced
ability of membrane repair in cancer cells compared with
the normal cells. This might contribute to the difference in
survival and effectivity of treatment on normal and cancer
cells and tissues when using permeabilization methods as
reported earlier (Lejbkowicz et al. 1993; Lejbkowicz and
Salzberg 1997; Marty et al. 2006; Neal et al. 2011;
Frandsen et al. 2015; Landstrom et al. 2015). Further
investigations are needed. A possible difference in mem-
brane repair might be caused by changes in the repair
mechanisms and/or membrane composition in cancer cells.
Membrane repair is a very complex system including
several mechanisms and involving numerous proteins
(Boucher and Mandato 2015). Many different Ca2?-sen-
sors are involved in membrane repair including calpains,
annexins, and S100 proteins. These sensors are activated by
the high Ca2? entry at the site of the injured membrane and
initiate the membrane repair process (McNeil et al. 2006;
Jaiswal et al. 2014; Boucher and Mandato 2015). Changes
in the expression of these proteins might change the
membrane repair mechanisms. Interestingly, expression of
S100 and annexin proteins has been shown to be changed
in many different cancer types (Bresnick et al. 2015; Wei
et al. 2015). Thus, it would be relevant to make further
investigation on the expression of these proteins in the 9
cell lines used in this study in order to test a possible
correlation with the shown membrane repair results. The
changed composition of lipids in the plasma membrane has
also been shown in cancer cells, such as more negative
charge, elevated levels of cholesterol, and the presence of
certain lipids in the outer and inner leaflet (Zwaal et al.
2005; Schweizer 2009). A changed membrane composition
might also affect membrane repair.
When treating cutaneous metastases with elec-
trochemotherapy in the clinic, the surrounding normal tis-
sue is less affected than the tumor tissue (Fig. 1) and it has
been proposed to be due to the increased effect of
chemotherapeutic drugs on fast-dividing cells as well as an
increased conductivity in tumor tissue increasing the per-
meabilization (Mir et al. 1996; Laufer et al. 2010). The
present study may supplement the previous explanations on
the clear difference in sensitivity of cancer and normal
cells treated with electrochemotherapy (Marty et al. 2006),
as well as after calcium electroporation (Frandsen et al.
2015), other electroporation-based therapies (Neal et al.
2011), and other therapies causing membrane permeabi-
lization such as sonoporation-based therapies (Lejbkowicz
et al. 1993; Lejbkowicz and Salzberg 1997) as well as
ionizing radiation (Hannig et al. 2000).
Conclusion
In conclusion, membrane repair was less effective in six of
the seven tested cancer cell lines and the immortalized cell
line compared with the normal primary fibroblasts. This
result could be part of the explanation why electroporation-
based therapies and other therapies permeabilizing the
plasma membrane are more effective in inducing cell death
of malignant than normal cells. However, further investi-
gations are needed to substantiate these results and inves-
tigate in more detail about membrane repair mechanisms
and membrane composition in the different cell lines.
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